Country: Canada
Language: English
Source: Health Canada
METOPROLOL TARTRATE
STRIDES PHARMA CANADA INC
C07AB02
METOPROLOL
1MG
SOLUTION
METOPROLOL TARTRATE 1MG
INTRAVENOUS
100
Prescription
BETA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0111923004; AHFS:
APPROVED
2020-08-13
_Page 1 of 37 _ PRODUCT MONOGRAPH PR METOPROLOL TARTRATE INJECTION, USP 1 mg/mL – 5 mL vial STERILE SOLUTION FOR INTRAVENOUS INJECTION ß-Adrenergic Receptor Blocking Agent Strides Pharma Canada Inc. 1565, Boul. Lionel-Boulet Varennes, Quebec Canada, J3X 1P7 Date of Revision: August 12, 2020 Submission Control No.: 241321 _Page 2 of 37 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 3 WARNINGS AND PRECAUTIONS .................................................................................. 4 ADVERSE REACTIONS .................................................................................................... 9 DRUG INTERACTIONS .................................................................................................. 11 DOSAGE AND ADMINISTRATION .............................................................................. 17 OVERDOSAGE ................................................................................................................ 19 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 20 STORAGE AND STABILITY .......................................................................................... 23 SPECIAL HANDLING INSTRUCTIONS ....................................................................... 23 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 24 PART II: SCIENTIFIC INFORMATION ............................................................................... 25 PHARMACEUTICAL INFORMATION .......................................................................... 25 DETAILED PHARMACOLOGY .................... Read the complete document